Cemacabtagene Ansegedleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of allogeneic, frozen, 'off-the-shelf', universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain and CD52 genes are deleted from the CAR19 T-cells. Upon administration, cemacabtagene ansegedleucel specifically targets and binds to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Deletion of the CD52 gene makes the modified donor T-cells resistant to the anti-CD52 monoclonal antibody alemtuzumab, which is used during lymphodepletion. The knockout of the TCR alpha gene eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells.

**Synonyms:** - ALLO 501A - ALLO-501A - ALLO501A - Allogeneic Anti-CD19 CAR T-cells ALLO-501A - Allogeneic Anti-CD19 CAR T-lymphocytes ALLO-501A - Allogeneic Anti-CD19 CAR-T Cells ALLO-501A - Allogeneic CD19-specific CAR T-cells ALLO-501A - CEMACABTAGENE ANSEGEDLEUCEL